Department of Medical-Surgical Sciences and Translational Medicine, Sant'Andrea Hospital, Sapienza University of Rome, Rome, Italy.
Gastroenterology Department, Portuguese Oncology Institute of Porto, Porto, Portugal.
Endoscopy. 2019 Jun;51(6):515-521. doi: 10.1055/a-0808-3186. Epub 2018 Dec 21.
Random biopsies are recommended to identify individuals at risk of gastric adenocarcinoma. Cumulative evidence suggests that narrow-band imaging (NBI) can be used to grade gastric intestinal metaplasia (GIM). We aimed to externally validate a classification of endoscopic grading of gastric intestinal metaplasia (EGGIM).
Consecutive patients in two centers were submitted to high resolution white-light gastroscopy followed by NBI to estimate EGGIM - a score (0 - 10) resulting from the sum of endoscopic assessments of GIM, scored as 0, 1, or 2 for no GIM, ≤ 30 %, or > 30 % of the mucosa, respectively, in five areas (lesser and greater curvature of both antrum and corpus, and incisura). If GIM was endoscopically suspected, targeted biopsies were performed; if GIM was not noticeable, random biopsies were performed according to the Sydney system to estimate the operative link on gastric intestinal metaplasia (OLGIM; the gold standard).
250 patients (62 % female; median age 55 years) were included. GIM was staged as OLGIM 0, I, II, III, IV in 136 (54 %), 15 (6 %), 52 (21 %), 34 (14 %), and 13 (5 %) patients, respectively. All patients with GIM except three were identifiable with targeted biopsies. For the diagnosis of OLGIM III/IV, the area under the ROC curve was 0.96 (95 % confidence interval [CI] 0.93 - 0.98) and by using the cutoff > 4, sensitivity, specificity, and positive likelihood ratio were 89 %, 95 %, and 16.5, respectively; results were similar (91 %, 95 %, and 18.1) when excluding patients with foveolar hyperplasia.
For the first time, an endoscopic approach was externally validated to determine the risk of gastric cancer without the need for biopsies. This can be used to simplify and individualize the management of patients with gastric precancerous conditions.
随机活检被推荐用于识别胃腺癌高危个体。累积证据表明,窄带成像(NBI)可用于胃肠上皮化生(GIM)的分级。我们旨在对胃肠上皮化生内镜分级(EGGIM)进行外部验证。
两个中心的连续患者接受高分辨率白光胃镜检查,然后进行 NBI 以估计 EGGIM- 一个分数(0-10),由胃 GIM 的内镜评估总和得出,分别在五个区域(胃窦和胃体的小弯和大弯,以及切迹)中无 GIM、≤30%或>30%的黏膜评为 0、1 或 2。如果 GIM 内镜可疑,则进行靶向活检;如果 GIM 不明显,则根据悉尼系统进行随机活检,以估计胃肠上皮化生的操作联系(OLGIM;金标准)。
250 例患者(62%为女性;中位年龄 55 岁)纳入研究。根据 OLGIM,GIM 分期分别为 0、I、II、III、IV 的患者分别为 136 例(54%)、15 例(6%)、52 例(21%)、34 例(14%)和 13 例(5%)。除 3 例外,所有有 GIM 的患者均能通过靶向活检识别。对于 OLGIM III/IV 的诊断,ROC 曲线下面积为 0.96(95%置信区间 0.93-0.98),当使用>4 的截止值时,灵敏度、特异性和阳性似然比分别为 89%、95%和 16.5;当排除有滤泡增生的患者时,结果相似(91%、95%和 18.1)。
首次对一种内镜方法进行了外部验证,该方法无需活检即可确定胃癌风险。这可用于简化和个体化有胃癌前病变患者的管理。